ClinicalTrials.gg
Not yet recruitingNCT06779318Updated Apr 3, 2025

Maintenance Chemotherapy With S-1 vs. Observation After Adjuvant Therapy for Resected Pancreatic Cancer With High Risk of Recurrence/Metastasis

A Phase 4 interventional study of S-1 in Pancreatic Cancer, Postoperative Adjuvant Therapy and Maintenance Therapy, sponsored by The First Affiliated Hospital with Nanjing Medical University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-04-03.

Sponsored by The First Affiliated Hospital with Nanjing Medical University · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
464
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies testing tegafur in Pancreatic Neoplasms — 3 open to participants now, 3 under way, none of them phase 3. Tegafur · Pancreatic Neoplasms.

Planned enrollment
2nd of 25
464 · median 60
Started
2025
the only one that year
Phase 4
2 of 26
1 open now
Registered
26th of 26
by date

Among the 26 studies testing tegafur in Pancreatic Neoplasms, this one is the 2nd largest by planned enrollment of the 25 interventional ones that give a count, is the only one that started in 2025, is one of 2 in phase 4, and was the 26th registered.

Pancreatic Neoplasms

3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

3 of the 26 studies testing tegafur in Pancreatic Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About tegafur

Tegafur: first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing tegafur in Pancreatic Neoplasms, or all of them as a file.
02

Study summary

The goal of this real-world study is to learn if maintenance chemotherapy with Tegafur, Gimeracil, and Oteracil Potassium (S-1) can improve disease-free survival (DFS) compared to follow-up observation in patients with resected pancreatic cancer at high risk of recurrence or metastasis after adjuvant therapy. The main questions it aims to answer are:

  • Does maintenance therapy with S-1 improve disease-free survival (DFS) compared to follow-up observation after standard treatment for resected high-risk pancreatic cancer?
  • Does S-1 maintenance therapy improve overall survival (OS), distant disease-free survival (DDFS), and local recurrence-free survival (LRFS) compared to observation?
  • What are the safety and tolerability profiles of S-1 maintenance therapy compared to observation? Researchers will compare two groups: the S-1 maintenance therapy group and the observation-only group, to see if S-1 improves survival outcomes and safety.

Participants will:

  • Receive maintenance chemotherapy with S-1 based on body surface area dosing or be assigned to the observation group without drug intervention.
  • Undergo imaging evaluations every 12 weeks to monitor for disease recurrence or metastasis.
  • Report side effects and any adverse events during the study.
03

Conditions studied

  • Pancreatic Cancer
  • Postoperative Adjuvant Therapy
  • Maintenance Therapy

Keywords

  • Maintenance Therapy
  • S-1
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed pancreatic cancer (originating from the pancreatic ductal epithelium);
  2. Meets one of the following conditions: Pathologically confirmed as moderately differentiated, moderately to poorly differentiated, or poorly differentiated; or pathologic staging as: T3N0M0, T1-3N1-2M0, T4N0-2M0; or one or more surgical margins are R1 resected (R0 resection if no tumor cells are found more than 1mm from the margin, otherwise R1 resection); or involvement of the portal vein and/or superior mesenteric vein resection; or pre- chemotherapy CA19-9 > 90 U/mL; or pre-adjuvant chemotherapy ctDNA testing positive;
  3. Completed standard treatment: Received radical resection, postoperative adjuvant therapy (including adjuvant chemotherapy based on gemcitabine or fluorouracil), and radiotherapy (if applicable);
  4. Eligible for oral medication;
  5. Age ≥18 and ≤75, male or female;
  6. performance status: 0 to 2;
  7. Normal function of major organs as per the following criteria within 14 days prior to starting treatment:① ≥ 1.5×10\^9/L;② count ≥ 75×10\^9/L;③ ≥ 9.0 g/dL;④ ≤ 2.5×UNL (upper normal limit) (if liver present, AST ≤ 5×UNL);⑤ ALT ≤ 2.5×UNL (if liver metastasis present, ALT ≤ 5×UNL);⑥ Total ≤ 1.5×UNL;⑦ (calculated using the Cockcroft-Gault formula) > 60 mL/min or serum creatinine ≤ 1.5×UNL;
  8. Women of must have used reliable within 7 days prior to enrollment and have a negative pregnancy test, and must be willing to use appropriate contraception during the study and for 6 months after the last dose of the drug. For men, they must be surgically sterile or agree to use appropriate contraception during the study and for 3 months after treatment;
  9. Expected survival time ≥6 months;
  10. Voluntary participation in the study, signed , and demonstrated good compliance and cooperation during follow-up.

Exclusion criteria

Exclusion Criteria:

  1. Pancreatic cancer originating from non-pancreatic ductal epithelium, including pancreatic neuroendocrine tumors, pancreatic acinar cell carcinoma, pancreatoblastoma, and solid-pseudopapillary tumor;
  2. Incomplete macroscopic resection (R2 resection);
  3. Presence of distant (including malignant ascites and pleural effusion, peritoneal metastasis) or locally recurrent pancreatic cancer;
  4. CA19-9 > 180 U/mL within 21 days before enrollment;
  5. Severe liver dysfunction (/ALT > 3.5 times the , alkaline phosphatase > 6 times the upper limit of normal), with liver drainage;
  6. Known peripheral neuropathy ( ≥ Grade 2);
  7. Participation in another clinical trial of cytotoxic drugs, targeted therapies, immunotherapies, etc., within the past 4 weeks, or received systemic chemotherapy, radiotherapy, or biological therapy within the past 4 weeks;
  8. Concurrent or metachronous cancers with disease-free survival ≥ 5 years (excluding pancreatic cancer), except for cancers that have been cured or can be potentially cured with local excision (e.g., esophageal cancer, gastric cancer, colorectal cancer, cervical cancer, non-melanoma skin cancer, bladder cancer);
  9. Factors that significantly affect oral drug absorption, such as difficulty swallowing, chronic diarrhea, or gastrointestinal obstruction; uncontrolled Crohn's disease or ulcerative colitis;
  10. Clinically symptomatic serous effusions (including pleural effusion, ascites, pericardial effusion) requiring symptomatic treatment;
  11. Pregnant or breastfeeding women; patients of unwilling or unable to take effective measures;
  12. Known allergy to the drug, the class of the investigational drug, or its components;
  13. Need for systemic treatment (except for local steroid pre-treatment);
  14. History of interstitial lung disease (including interstitial pneumonia, pulmonary fibrosis, etc.) or CT findings of interstitial lung disease;
  15. Active local or systemic infection requiring treatment;
  16. Heart failure classification ≥ II or severe heart disease;
  17. Known infection or history of acquired immunodeficiency syndrome (AIDS) or active or C;
  18. Toxicity not recovered (CTCAE > Grade 1) or previous anticancer surgery not fully recovered;
  19. Patients deemed unsuitable for this study by the investigator.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
464 participants (estimated)

Study arms

  • Experimental
    S-1 Maintenance Therapy

    S-1 monotherapy

    Drug: S-1

  • No intervention
    Observation Only

    Participants in this arm will undergo follow-up observation according to the trial protocol, without receiving any antineoplastic drugs for maintenance therapy.

Interventions

06

What researchers measure

Primary outcomes

  1. Disease-Free Survival (DFS)

    Disease-Free Survival (DFS) is defined as the time from enrollment to the first occurrence of disease recurrence or death from any cause, whichever occurs first. If no recurrence occurs during the study, DFS is defined as the time from enrollment to the last confirmed date of disease-free status. For participants who withdraw from the study for reasons other than recurrence (e.g., initiation of other treatments), DFS will be censored at the time of withdrawal or the start of other treatment. For participants who are not censored, pre-planned sensitivity analyses will be conducted based on radiologically confirmed recurrence or death. New primary tumors will not be considered as recurrence events. The confirmed recurrence date will be the date of imaging showing relapse. If recurrence is confirmed through other clinical methods, the date of diagnosis will be used.

    Time frame: Up to 3 years

Secondary outcomes

  1. Overall Survival (OS)

    Overall Survival (OS) is defined as the time from enrollment to death from any cause. For participants who are alive at the last follow-up, OS will be censored at the last known date of survival. In cases of participants lost to follow-up, OS will be censored at the last date they were confirmed to be alive.

    Time frame: 5 years

  2. Distant Disease-Free Survival (DDFS)

    Distant Disease-Free Survival (DDFS) is defined as the time from enrollment to the first occurrence of distant metastasis or death from any cause, whichever occurs first. If no distant metastasis occurs, DDFS will be defined as the time from enrollment to the last confirmed date of no distant metastasis.

    Time frame: Up to 3 years

  3. Local Recurrence-Free Survival (LRFS)

    Local Recurrence-Free Survival (LRFS) is defined as the time from enrollment to the first occurrence of local recurrence or death from any cause, whichever occurs first. If no local recurrence occurs, LRFS will be defined as the time from enrollment to the last confirmed date of no local recurrence.

    Time frame: Up to 3 years

  4. Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v5.0

    This outcome will assess the number of participants who experience treatment-related adverse events, graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. These events will be monitored and categorized based on severity, with a focus on the relationship to the study treatment.

    Time frame: Up to 3 years

  5. Quality of Life (QoL)

    Quality of Life will be measured using the EORTC QLQ-C30 (version 3), a widely used instrument to assess the health-related quality of life of cancer patients. The scores will be analyzed to evaluate changes in the quality of life during the study period.

    Time frame: Up to 3 years

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2025; primary completion for Jul 2027, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2025
First posted
Jan 16, 2025
StartEst.
Jul 2025
Primary completionEst.
Jul 2027
CompletionEst.
Jul 2028
Last update
Apr 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06779318
Responsible party
Min Tu (Associate Chief Physician, The First Affiliated Hospital with Nanjing Medical University) — Principal investigator
First posted
Jan 16, 2025
Start date
Jul 2025 (estimated)
Primary completion
Jul 2027 (estimated)
Completion
Jul 2028 (estimated)
Last update
Apr 3, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tegafur · Gimeracil · Oxonic Acid

Start the discussion